市場調查報告書
商品編碼
1276428
醫學仿生學全球市場規模、份額和行業趨勢分析報告:按疾病類型、應用(傷口癒合、組織工程、藥物輸送等)、區域展望和預測,2023-2029 年Global Medical Biomimetics Market Size, Share & Industry Trends Analysis Report By Disease Type, By Application (Wound Healing, Tissue Engineering, Drug Delivery and Others), By Regional Outlook and Forecast, 2023 - 2029 |
醫療保健領域的仿生學市場規模預計到 2029 年將達到 577 億美元,預測期內復合年增長率為 6.9%。
對於仿生學、仿生學或仿生學的應用和轉化人類應用,闡明令人興奮的自然系統的功能和結構之間的潛在機制和聯繫是單一的,無論是作為個人還是群體、健康的最終用戶/消費者或患者邀請需要治療的患者進行類似的患者旅程。 仿生學是一個跨學科領域,它利用化學、工程學和生物學的原理來創造模擬生物過程的材料、機器或合成系統。
基於仿生學的設計有望應用於藥物輸送、再生醫學和組織工程。 藥學和醫學領域的仿生學在對抗癌症等危及生命的疾病方面也顯示出巨大潛力。 醫學仿生學市場的快速擴張主要是由於政府增加了對仿生學研究的投資,以及醫療保健領域醫學工程和納米技術的整合和進步。
COVID-19 影響分析
隨著隔離的放鬆、疫苗接種的好處和 COVID-19 病例的減少,企業正在恢復程序以滿足對其產品的需求。 許多國家的檢疫和大流行情況正在改善,並且有明顯的複蘇趨勢。 一些從業者通過實踐本地和國際指導來開始他們的服務。 此外,醫療保健領域仿生學銷量的增加、仿生學產品的技術進步、政府為減輕疾病負擔所做的努力、監管部門的批准等,都增加了預測期內仿生學在醫療保健領域的市場份額。 因此,預計這些發展將在預測期內穩定市場並引發增長。
市場增長因素
人口的永久老齡化將增加對仿生學的需求
老齡化社會是影響新興國家的最重要問題之一。 此外,心髒病、外周動脈疾病和靜脈血栓栓塞等慢性病在老年人中的流行預計會增加醫療保健領域對仿生學的需求和採用。 根據美國疾病控制和預防中心的一項研究,到 2020 年,近 27% 的男性和超過 21% 的女性將患有外周血管疾病,超過 19.1% 的 55 至 65 歲人群將受到影響。 與人口老齡化相關的疾病患病率不斷上升,以及仿生學在患者護理中的使用越來越多,這將推動市場增長。
納米技術的市場開發支持市場增長
在預測期內,納米技術創新推動藥物輸送系統的進步預計將對醫學仿生學的發展產生積極影響。 納米材料對生物醫學應用具有吸引力,並基於其生物相容性、物理和化學特性在仿生醫學中顯示出巨大潛力。 仿生功能化納米技術的發展使得利用源自細胞膜的成分對納米材料進行功能化和改性成為可能,從而使仿生納米材料具有更高的穩定性、生物相容性、特異性和靶向性。 因此,將仿生納米材料用於非侵入性疾病診斷可能會在預測期內推動市場增長。
市場製約因素
與醫學仿生學相關的高成本
仿生技術的開發需要復雜的製造程序,這會導致高昂的開發和製造成本。 這可以降低價格和可用性,使患者更難獲得。 此外,細胞和基因療法非常昂貴,因為製造傳統藥物和生物藥物所需的化學物質比細胞和病毒載體更難處理。 因此,對於典型的生物製藥,接受該藥物治療的患者數量將增加一倍,達到數千,甚至數百萬。 因此,預計與醫療保健中的仿生學相關的高成本將阻礙預期期間的市場增長。
疾病類型的前景
醫療仿生學市場按疾病類型分為眼科、心血管科、骨科、牙科等。 2022 年,心血管領域在醫療保健領域的仿生學市場實現了大幅增長。 這是因為心血管疾病是全世界死亡的主要原因,每年有 1790 萬人死亡。 每年有超過 210 萬人植入 CVD 植入物以延長壽命。 作為一個額外的好處,在預測期內,該細分市場將受益於引入技術先進的產品和政府資金所帶來的有利機會,這將增加仿生學在醫療保健中的使用,從而增加該細分市場的增長可能會加速。
使用展望
醫療仿生學市場按應用細分為傷口癒合、組織工程、藥物輸送等。 到 2022 年,傷口癒合部分將佔醫療保健仿生學市場的最大收入份額。 這是由於手術病例的增加和慢性病發病率的上升,增加了對促進傷口癒合和傷口護理的產品的需求。 教育材料和仿生學的進步使得將纖維化傷口癒合轉移到再生過程變得越來越有利。
區域展望
按地區劃分,對北美、歐洲、亞太地區和拉美地區的醫療保健仿生學市場進行了分析。 到 2022 年,北美地區將在仿生學市場中產生最高的收入份額。 這是由於需要牙科仿生產品的牙科疾病增加,政府對仿生產品研究的支持力度加大,以及發達國家資本收入的顯著增加。 此外,已經存在並努力降低支出水平的先進報銷機制也有助於擴大市場。 因此,這些因素正在推動北美地區醫療仿生學市場的增長。
The Global Medical Biomimetics Market size is expected to reach $57.7 billion by 2029, rising at a market growth of 6.9% CAGR during the forecast period.
A medical product category, medical biomimetics, was created by taking design cues from natural components. Problems relating to cardiac diseases, orthopedic diseases, ocular diseases, and dental diseases are resolved using medical biomimetics. Drug delivery and tissue regeneration are two medical applications of biomimicry.
In order to use natural systems and organisms as the basis for new scientific, technical, and technological solutions suitable for interventional use in dentistry and medicine, including tissue bio-engineering, biomimicry is a fusion of approaches needing the detection, perception, observation, identification, and close study of these entities.
A similar journey invites elucidating the underlying mechanisms and connections between the function and structure of the stimulating natural system(s) for applied and translational biomimetics, biomimicry, or biomimetics to humans, whether as single individuals or in groups and when healthy end-users/consumers or patients in need of therapies. Biomimetics is a multidisciplinary field that utilizes principles from chemistry, engineering, and biology to create materials, machines, or synthetic systems that mimic biological processes.
Biomimetics-based designs have potential applications in drug delivery, regenerative medicine, and tissue engineering. In addition, utilizing biomimetics in the field of pharmaceutics and medicine shows great potential for addressing life-threatening illnesses such as cancer. The rapid expansion of the medical biomimetics market is primarily fueled by heightened government investment in biomimetics research, as well as the integration and advancements of medical engineering and nanotechnology in the healthcare sector.
COVID-19 Impact Analysis
Companies have restarted their procedures to fulfill the demand for products, as a result of the easing of lockdowns, the advantages of vaccinations, and a drop in COVID-19 cases. Quarantine and the pandemic scenario are getting better and clearly on the mend in many nations. Several practitioners have launched their services by putting local and international guidance into practice. Additionally, the market share for medical biomimetics increased during the forecast period due to increased sales of medical biomimetics, technological advancements in biomimetic products, government initiatives to lessen the burden of disease, and regulatory approval. Therefore, it is anticipated that these trends will stabilize the market and cause it to grow over the course of the forecast period.
Market Growth Factors
The constant aging of the population raises the demand for biomimetics
The growing older population is one of the most important concerns impacting emerging nations globally. It is also projected that the prevalence of chronic conditions in the elderly, such as heart disease, peripheral artery disease, and venous thromboembolism, will increase demand for and adoption of medical biomimetics. According to research by the Centers for Disease Control and Prevention, nearly 27% of men and more than 21% of women will have peripheral vascular disease in 2020, affecting more than 19.1% of people aged 55 to 65. As a result of expanding uses of biomimetics in patient care joined with the increasing number of diseases due to the aging population will aid in the market growth.
Growing nanotechnology development to support the market growth
The advancements in drug delivery systems brought about by nanotechnology innovations will positively affect the growth of medical biomimetics during the forecast period. Nanomaterials are appealing for biomedical applications and show tremendous potential in biomimicry medicine based on their biocompatibility, physical and chemical properties. The development of biomimetic functionalized nanotechnology has allowed for the functionalization and modification of nanomaterials by components obtained from cell membranes, resulting in biomimetic nanomaterials with improved stability, biocompatibility, specificity, and targeting. Thus, using biomimetic nanomaterials for non-invasive disease diagnosis can aid the market growth during the projected period.
Market Restraining Factors
High cost associated with medical biomimetics
The complicated manufacturing procedures needed to create biomimetic technology might make them expensive to develop and produce. This may reduce its accessibility to patients by lowering its pricing and availability. In addition, because it is much more difficult to work with the chemicals needed to make traditional pharmaceuticals and even biopharmaceuticals than working with cells or viral vectors, cell and gene therapies have become much more expensive. As a result, the number of patients who will receive the drug is multiplied by thousands or millions for typical biopharmaceuticals. Thus, the high cost associated with medical biomimetics is anticipated to hamper the market growth during the anticipated period.
Disease Type Outlook
Based on disease type, the medical biomimetics market is characterized into ophthalmology, cardiovascular, orthopedic, dental, and others. The cardiovascular segment procured a considerable growth rate in the medical biomimetics market in 2022. This is because, with 17.9 million deaths annually, CVD is the leading cause of death globally. Every year, more than 2.1 million people have CVD implants to prolong their lives. Additionally, during the forecast period, the segment will benefit from lucrative opportunities brought on by the introduction of technologically advanced products and government funding, which will increase the utilization of medical biomimetics and thereby surge the segment's growth.
Application Outlook
On the basis of application, the medical biomimetics market is classified into wound healing, tissue engineering, drug delivery, and others. The wound healing segment witnessed the largest revenue share in the medical biomimetics market in 2022. This is owing to a growing number of surgical cases and the rise in the incidence of chronic diseases, increasing the demand for products promoting wound healing and wound care. It is becoming increasingly advantageous to reroute fibrotic wound healing toward a regeneration process by advancing instructional materials and biomimetics.
Regional Outlook
Region wise, the medical biomimetics market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generate the highest revenue share in the medical biomimetics market in 2022. This is due to increased dental disorders that necessitate dental biomimetics goods, increased government support for biomimetics product research, and a considerable increase in capital income in industrialized countries. In addition, the sophisticated reimbursement mechanism that already exists and strives to lower expenditure levels also contributes to the market's expansion. As a result, these elements fuel the medical biomimetics market growth in the North America region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zimmer Biomet Holdings, Inc., BioHorizons, Inc. (Henry Schein, Inc.), SynTouch Inc., CorNeat Vision Ltd., Osteopore International Pte Ltd, Curasan, Inc., Otsuka Medical Devices Co., Ltd. (Otsuka Holdings Co. Ltd.), Swedish Biomimetics 3000 ApS, Keystone Dental Group and Blatchford Limited.
Strategies Deployed in Medical Biomimetics Market
Oct-2022: CorNeat has launched EverMatrix tissue integrating material technology. Evermatrix features a 100% synthetic biomimetic extracellular matrix that merges with human tissue for a lifetime. It also features a flexible and tough body structure that maintains its form when drenched.
Jul-2022: Curasan AG launched CERASORB CPC bone fillers.CERASORB CPC features phosphate and calcium salts dispersed in biocompatible oil made from plant extracts. The product is used mainly for minimally invasive applications. By introducing this product, curasan AG has strengthened its position in the market by countering the problems faced by medical personnel due to following a rigid protocol during the treatment of the wound.
Apr-2022: Keystone Dental Group has teamed up with Milestone Scientific for a channel partnership regarding Milestone's STA Single Tooth Anesthesia System. The collaboration aims at providing better patient care for Keystone's customers.
Sep-2021: Keystone Dental Inc. took over Osteon Medical. The acquisition strengthens Keystone's position in the dental market and provides sales opportunities for its synergistic and expanded implants. Furthermore, Keystone would be able to serve its customers in a better way owing to the combined portfolio of the company after the acquisition.
Mar-2021: CorNeat has partnered with LiveU, a remote solution production and video streaming company, for developing Remote Surgeon Virtual Presence (RSVP) Solution. The new solution would allow CorNeat to spread its clinical trials to more sites. RSVP also serves as a compliment for launching Corneat Kpro to train surgeons virtually across the globe.
Jan-2021: Osteopore International has teamed up with Maastricht University Medical Centre to develop a bone implant solution that averts leg amputation. This collaboration is directed at the adoption of 3D-printed bioresorbable implants across a wide clinical base.
Aug-2020: Blatchford Limited has unveiled ElanIC, a firm, and lightweight microprocessor-enabled hydraulic ankle. ElanIC features a lightweight and compact waterproof design that provides greater comfort to the user. Furthermore, the prosthetic features a standing support mode to improve the resistance when the user is stationary. The benefits of the prosthetic include reduced risk of trips, increased walking speed, improved ground clearance, and enhanced control.
Market Segments covered in the Report:
By Disease Type
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures